OCTA in Mild Cognitive Impairment and Alzheimer's Disease
-
- STATUS
- Recruiting
-
- End date
- Dec 31, 2022
-
- participants needed
- 1000
-
- sponsor
- Duke University
Summary
This study aims to develop and evaluate biomarkers using non-invasive optical coherence tomography angiography (OCTA) to assess the structure and function of the retinal microvasculature in persons with mild cognitive impairment (MCI) and Alzheimer's Disease (AD), Parkinson's Disease (PD) or other neurodegenerative disease, multiple sclerosis, and Huntington's disease.
Description
Using a multidisciplinary approach, this study aims to yield new insight into the vascular pathophysiology of mild cognitive impairment (MCI) and Alzheimer's Disease (AD) Parkinson's Disease (PD) or other neurodegenerative disease. The investigators propose to develop and evaluate biomarkers using non-invasive optical coherence tomography angiography (OCTA) to assess the structure and function of the retinal microvasculature in persons with MCI and AD, PD or other neurodegenerative disease multiple sclerosis, and Huntington's disease..
The investigators hypothesize that microvascular network alterations in the retina mirror and possibly precede changes in the cerebral microcirculation seen in these diseases. Using advanced image analysis, the investigators aim to evaluate markers of reduced capillary blood flow and non-perfusion in the superficial and deep retinal vascular plexuses and choriocapillaris imaged using OCTA, in a resolution not previously possible, that would complement already established retinal structural markers and increase their sensitivity and specificity in the early detection of MCI and AD, PD, multiple sclerosis, and Huntington's disease. or other neurodegenerative disease.
This study looks to provide a proof of concept for OCTA-based retinal microvascular biomarkers as an effective screening tool in cognitive aging.
Details
| Condition | Alzheimer Disease, Mild Cognitive Impairment, Retinal Vascular, Parkinson Disease, Multiple Sclerosis, Huntington Disease, Neuro-Degenerative Disease |
|---|---|
| Treatment | Retinal Imaging |
| Clinical Study Identifier | NCT03233646 |
| Sponsor | Duke University |
| Last Modified on | 25 January 2022 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer